drugset / Trial / NCT02234921
Pilot Study of DRibble Vaccine for Prostate Cancer Patients
Phase 1
Completed
3 enrolled
UbiVac
Providence Cancer Center · collabProvidence Cancer Center, Earle A. Chiles Research Institute · collabProvidence Health & Services · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.
Timeline
- Start
- 2014-10-24
- Primary completion
- 2018-08-15
- Completion
- 2018-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cervarix | Vaccine | 0.5 ml | Intramuscular |
| Subject | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Subject | DRibble vaccine | Vaccine | — | Other |
| Subject | Imiquimod | Other / unclassified | 5 % | Topical |
| Subject | Imiquimod | Other / unclassified | 250 mg | Topical |